Diabetes mellitus is a major cause of cardiovascular morbidity and mortality in the United States. Enhanced platelet function participates in the pathogenesis of vascular complications. We have recently observed that there is significant thromboxane release from diabetic platelets particularly during hyperglycemia and that aldose reductase may play a significant role in promoting platelet hyperactivity. Our goals are to discover the mechanism by which hyperglycemia is transduced into thromboxane release contributing to diabetic platelet dysfunction. Through three Specific Aims we will initially addres the role of aldose reductase in transducing this high glucose signal to platelet dysfunction (Specific Aim #1).
Specific Aim #2 will determine whether this signaling process may contribute to aspirin insensitivity that is often observed among diabetic patients, and Specific Aim #3 will assess how newly discovered genetic variants may influence both the response to hyperglycemia and aspirin insensitivity. At the conclusion of this research program we will have identified and confirmed a key metabolic and signaling component that transduces acute and chronic hyperglycemia into enhanced platelet activity. The results of these studies may support proceeding with clinical trials to determine what combination of antiplatelet agents would be most beneficial to protect against cardiovascular disease in diabetic patients.

Public Health Relevance

Platelet hyperactivity in diabetic patients plays an important role in the development of cardiovascular disease. We will now explore the glucose specific mechanisms for this increase in thrombosis, by complementing human, mouse and tissue culture cell systems. Our proposed biochemical, genetic and signaling studies may assist in the development of new antiplatelet drugs for diabetic patients, in combating cardiovascular disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL115247-04
Application #
8895384
Study Section
Clinical and Integrative Diabetes and Obesity Study Section (CIDO)
Program Officer
Warren, Ronald Q
Project Start
2012-08-01
Project End
2016-07-31
Budget Start
2015-08-01
Budget End
2016-07-31
Support Year
4
Fiscal Year
2015
Total Cost
$410,006
Indirect Cost
$163,756
Name
Yale University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06510
Wang, Dandan; Hu, Xiaoyue; Lee, Seung Hee et al. (2018) Diabetes Exacerbates Myocardial Ischemia/Reperfusion Injury by Down-Regulation of MicroRNA and Up-Regulation of O-GlcNAcylation. JACC Basic Transl Sci 3:350-362
Zou, Siying; Teixeira, Alexandra M; Kostadima, Myrto et al. (2017) SNP in human ARHGEF3 promoter is associated with DNase hypersensitivity, transcript level and platelet function, and Arhgef3 KO mice have increased mean platelet volume. PLoS One 12:e0178095
Jin, Yu; Xie, Yi; Ostriker, Allison C et al. (2017) Opposing Actions of AKT (Protein Kinase B) Isoforms in Vascular Smooth Muscle Injury and Therapeutic Response. Arterioscler Thromb Vasc Biol 37:2311-2321
Xiang, Yaozu; Hwa, John (2016) Regulation of VWF expression, and secretion in health and disease. Curr Opin Hematol 23:288-93
Chae, Wook-Jin; Ehrlich, Allison K; Chan, Pamela Y et al. (2016) The Wnt Antagonist Dickkopf-1 Promotes Pathological Type 2 Cell-Mediated Inflammation. Immunity 44:246-58
Lee, Seung Hee; Du, Jing; Stitham, Jeremiah et al. (2016) Inducing mitophagy in diabetic platelets protects against severe oxidative stress. EMBO Mol Med 8:779-95
Zou, Siying; Teixeira, Alexandra M; Yin, Mingzhu et al. (2016) Leukaemia-associated Rho guanine nucleotide exchange factor (LARG) plays an agonist specific role in platelet function through RhoA activation. Thromb Haemost 116:506-16
Stitham, J; Hwa, J (2016) Prostacyclin, Atherothrombosis and Diabetes Mellitus: Physiologic and Clinical Considerations. Curr Mol Med 16:328-42
Xiang, Yaozu; Cheng, Jijun; Wang, Dandan et al. (2015) Hyperglycemia repression of miR-24 coordinately upregulates endothelial cell expression and secretion of von Willebrand factor. Blood 125:3377-87
Moore, Jason H; Hwa, John (2014) Editorial: pharmacogenetics and molecular medicine: ""so close and yet so far"". Curr Mol Med 14:803-4

Showing the most recent 10 out of 25 publications